Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGAST: Oral Budesonide for Prevention of Acute GI GVHD
NCT00180089Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2004
- Primary completion
- Mar 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Budesonide with Placebo (2 arms). Primary endpoint: Incidence of Acute Gastrointestinal Graft-versus-host Disease. Started Jan 2004; status: completed.
02
Drugs
budesonide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00180089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180089.